Largest Shareholder's Stake Slightly Increases to 37.93%... Insider Buying and Collateral Extension Maintains Management Stability


  • The combined stake of largest shareholder Nam Young-woo and his special relations increased by 0.06%p to 37.93% compared to the previous report. This resulted from open market purchases by three executives (Kim Young-kwan, Kim Sung-kyu, Choi Hae-sung) totaling 12,650 shares, with an average acquisition price of approximately KRW 3,860~3,960 per share.
  • Nam Young-woo's personal holdings remained unchanged at 1,815,237 shares (8.58%), while the affiliated company Woogyung Co., Ltd. holds the largest block with 5,069,457 shares (23.96%). The reporter stated the purpose is to influence management.
  • Three stock collateral contracts under Woogyung were extended: NH Investment & Securities (523,082 shares, maintenance ratio 150%), Shinhan Bank (1,057,991 shares), and KB Kookmin Bank (2,000,000 shares), totaling 3,581,073 shares (16.92%). The aggregate loan amount is approximately KRW 5.5 billion (KRW 1.5B, 2B, 2B respectively), used for Woogyung's operating funds.
  • This filing reflects minor insider buying and extension of existing collateral, with no new capital raising or dilution. Thus, the impact on shareholder value is limited.
  • [AI Comprehensive Analysis]The disclosure is largely a routine report with a slight increase in insider holdings and collateral extension, posing no significant short-term implications for stock price or investment risk. It primarily confirms management stability.

KOSPI Filing Information


  • Filing: Report on Large Shareholding (General)
  • Company: Kukje Pharma (002720)
  • Submission: Nam Young-woo
  • Receipt: 05-29-2026